Actinium Pharma wins Canadian patent allowances for Actimab-A, Iomab-ACT programs

Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.

ATNM

0.00

  • Actinium Pharmaceuticals received Canadian Notices of Allowance for two patents covering Actimab-A in AML, Iomab-ACT conditioning for gene-edited cell therapies.
  • Actimab-A application covers use with CLAG-M chemotherapy for AML; Canadian patent term expected to run into January 2039.
  • Iomab-ACT application covers CD45-targeted conditioning for gene-edited cell-based therapies; Canadian patent term expected to run into October 2038.
  • Company cited a global patent estate of about 250 issued, pending patents, patent applications across key markets including the U.S., Europe, China, Japan.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605291731PR_NEWS_USPR_____NY71690) on May 29, 2026, and is solely responsible for the information contained therein.